.png){kind=icon}
.png){kind=icon}
Return
Strategies toward Renewable and Compostable Intravenous Bag Materials
.png){kind=icon}
PRE
AI
DOI：10.1021/acsabm.5c02054.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
The medical industry contributes significantly to single-use plastic waste, as illustrated most recently by the COVID-19 pandemic. While safety standards mandate the use of disposable, single-use items for the highest-value applications, there is an opportunity to pursue greater circularity in higher-volume, bulk plastic goods, including intravenous (IV) bags. Herein, we assessed two thermoplastic elastomers based on renewable, compostable poly(gamma-methyl-epsilon-caprolactone) (P gamma MCL) as IV bag material alternatives to the nonrenewable, potentially harmful phthalate-plasticized poly(vinyl chloride) (PVC) industry standard. We synthesized a thermoplastic poly(urethane-urea) (TPUU) and 4-arm P gamma MCL-b-poly((-)-lactide) star-block polymer ((ML)(4)) on >55 g scales and comprehensively evaluated their mechanical and (bio)chemical readiness for an IV bag application. The TPUU showed excellent mechanical parity with PVC, and both P gamma MCL-based materials displayed superior cytocompatibility to PVC. An in vivo implantation study in a rat model revealed no significantly adverse histopathology resulting from direct tissue contact with the TPUU or (ML)(4.) The P gamma MCL-based materials also conform to ISO-standardized chemical hazard thresholds similarly to PVC. Our work is the first to target IV bag waste through direct replacement of current materials with intrinsically circular polymers, providing an evaluation framework for future IV bag candidates and expanding P gamma MCL's application scope to the biomedical sector.
Keywords:
sustainable materials
medical devices
blockpolymers
polyesters
in vivo implantation
Journal
IF:
4.7
Papers:
858
Citations:
1.6W